NUS at a glance
NU SKIN ENTERPRISES, INC. (NUS, SEC CIK 1021561) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on August 21, 2026 and Form 4 insider filings as recently as September 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), NU SKIN ENTERPRISES, INC. (NUS) reported revenue of $1.5 billion (down 14.3% from FY2024) and net income of $160.2 million. Diluted EPS was $3.18.
- As of June 30, 2026, 29 institutional investment managers tracked by SignalX reported holding NU SKIN ENTERPRISES, INC. (NUS) shares worth $103.0 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Nathanson Laura on May 11, 2026 of 2,676 shares at $6.73 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.5B
- −14.3% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 29 funds
- $103.0M · +0 vs prior quarter
- Latest 8-K
- Aug 21, 2026
- Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $320.1M, down 17.1% YoY from $386.1M
- Gross margin 68.2% vs 68.8% YoY; effective tax rate (295.4)% vs 23.0%
- Best segment Hong Kong/Taiwan: contribution margin 30.2%; worst Rhyz Other: (17.6)% margin
- Goodwill impairment charge $78.9M and U.S. deferred-tax valuation allowance $167.5M
- India opening delayed to first half 2027; Q3 anticipated $5.0M LIVE! expense and $5.0M transition costs
Risk Factors
- No new or changed risk factors; company reported no material changes from the 2025 Form 10-K
- Liquidity risk increased after a $30 million revolving-credit draw, bringing total borrowings to $70 million
- Near-term repayment pressure from anticipated $25 million revolving-credit repayment during Q3 2026
- Regulatory risk unchanged across previously disclosed compliance exposures in the 2025 Form 10-K
AI summary of the NUS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Justin Keisel began a medical leave August 17, 2026, creating temporary leadership uncertainty for Global Sales
- COO and Chief Legal Officer Chayce Clark will lead Keisel’s organization during the absence
Item 2.02: Results of Operations and Financial Condition
- Section contains only boilerplate incorporation-by-reference language
- No fiscal-year 2026 operating results or financial metrics disclosed in the provided text
Item EX-99.1: Item EX-99.1
- Q2 revenue $320.1M, down 17.1% year over year; broad weakness across Nu Skin and Rhyz segments
- GAAP EPS $(5.14), including $78.9M impairment and $167.5M deferred-tax valuation allowance; adjusted EPS $0.20
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Shareholders approved 2,850,000 additional shares for equity incentive awards
- Expanded share pool creates potential dilution for existing shareholders
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders re-elected all nine directors, supporting board continuity through the next annual meeting
- Executive compensation advisory vote approved, with 33,111,458 votes for and 1,255,101 against
AI summaries of NUS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for NUS
Don't miss the next NUS filing
- Alerts as it files. A push when NUS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NUS, by share count.
- Ask anything. An AI agent that reads every NUS filing and answers with sources.
NUS alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| WOODBURY EDWINA D | A | Sep 9, 2026 | 22 | $4.85 |
| WOODBURY EDWINA D | A | Jun 10, 2026 | 19 | $5.43 |
| Nathanson Laura | Sell | May 11, 2026 | 2,676 | $6.73 |
| WOODBURY EDWINA D | A | Mar 11, 2026 | 14 | $7.31 |
| Keisel Justin S | A | Mar 6, 2026 | 47,059 | - |
| Clark Chayce David | A | Mar 6, 2026 | 138,971 | - |
| Hatchett Steven Keith | A | Mar 6, 2026 | 77,941 | - |
| Thomas James D | A | Mar 6, 2026 | 114,706 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.7B | $1.5B |
| Gross Profit | - | $1.2B | $1.0B |
| Operating Income | - | -$151.6M | $65.8M |
| Net Income | - | -$146.6M | $160.2M |
| Gross Margin | - | 68.2% | 69.4% |
| Op. Margin | - | -8.8% | 4.4% |
| Net Margin | - | -8.5% | 10.8% |
| Balance Sheet | |||
| Total Assets | $1.8B | $1.5B | $1.4B |
| Equity | $822.0M | $651.5M | $805.2M |
| ROE | - | -22.5% | 19.9% |
| Per Share | |||
| EPS | - | $-2.95 | $3.18 |
| Cash Flow | |||
| Operating CF | - | $111.7M | $80.3M |
| CapEx | - | $41.6M | $34.3M |
Source: XBRL data in NU SKIN ENTERPRISES, INC. (NUS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate NUS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 29 | $103.0M |
| Q1 2026 | 29 | $138.8M |
| Q4 2025 | 27 | $181.5M |
| Q3 2025 | 28 | $239.7M |
| Q2 2025 | 28 | $159.2M |
| Q1 2025 | 25 | $123.2M |
| Q4 2024 | 20 | $90.2M |
| Q3 2024 | 19 | $75.3M |
- Prudential Financial+549.5K (+146%)
- Citadel Advisors LLC+427.2K (+188%)
- Two Sigma Investments+156.5K (+15%)
- Morgan Stanley+75.2K (+9%)
- Dimensional Fund Advisors+61.6K (+4%)
- AQR Capital Management−447.2K (-36%)
- Goldman Sachs Group−130.0K (-17%)
- Renaissance Technologies LLC−92.8K (-5%)
- JPMorgan Chase & Co−64.7K (-31%)
- D.E. Shaw & Co−63.4K (-14%)
- Ameriprise Financial+43.0K
- Millennium Management−110.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 205 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NUS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 10, 2026 | - | - | - |
| 8-K | Aug 21, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | May 29, 2026 | - | Analysis | |
| 4 | May 12, 2026 | - | - | |
| 8-K | May 8, 2026 | - | Analysis | |
| 10-Q | May 8, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 8-K | Mar 27, 2026 | - | - | - |
| 8-K | Mar 20, 2026 | - | - | - |
| 4 | Mar 12, 2026 | - | - | - |
| 4 | Mar 9, 2026 | - | - | - |
| 4 | Mar 9, 2026 | - | - | - |
| 4 | Mar 9, 2026 | - | - | - |
| 4 | Mar 9, 2026 | - | - | - |
| 8-K | Mar 9, 2026 | - | Analysis | - |
| 4 | Mar 9, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Feb 18, 2026 | - | - |
Related Health Care companies
- CAH · Cardinal HealthWholesale-Drugs, Proprietaries & Druggists' Sundries
- COR · CencoraWholesale-Drugs, Proprietaries & Druggists' Sundries
- HLF · HERBALIFE LTD.Wholesale-Drugs, Proprietaries & Druggists' Sundries
- MCK · McKesson CorporationWholesale-Drugs, Proprietaries & Druggists' Sundries
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
NUS SEC filings: frequently asked questions
Which institutions hold NUS stock?
As of June 30, 2026, the largest NU SKIN ENTERPRISES, INC. (NUS) holders among the 13F filers tracked by SignalX were BlackRock ($22.8 million), Vanguard Capital Management LLC ($10.8 million), Dimensional Fund Advisors ($9.5 million), Vanguard Portfolio Management LLC ($9.2 million), Renaissance Technologies LLC ($8.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was NUS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), NU SKIN ENTERPRISES, INC. (NUS) reported revenue of $1.5 billion (down 14.3% from FY2024) and net income of $160.2 million. Diluted EPS was $3.18. The figures come from the XBRL data in the 10-K.
What did NUS report in its latest 8-K?
NU SKIN ENTERPRISES, INC. (NUS) filed an 8-K on August 21, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Justin Keisel began a medical leave August 17, 2026, creating temporary leadership uncertainty for Global Sales.
What are the latest NUS SEC filings?
NU SKIN ENTERPRISES, INC. (NUS) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on August 21, 2026 and a Form 4 insider filing on September 10, 2026.
What is NUS's SEC CIK number?
NU SKIN ENTERPRISES, INC. (NUS)'s SEC Central Index Key (CIK) is 1021561. EDGAR lists every NUS filing under that number.
Ask anything about NUS
The research agent reads NUS's filings, financials, insider trades and 13F holders, then answers with sources.